* EEs down 16% to 2.6m, SEK 4.6m installations, EBIT 7% above us * Opex, market and installation tai...
* Weaker sales and maintained opex behind estimate cuts * We see relatively unchanged FCF '26e (SEK ...
* Annual revenue exceeds MSEK 200 * The bottom line disappoints in Q4 * We keep our fair value of SE...
Redeye provides an initial comment on Scandinavian ChemoTech’s Q4 2025 report.
Redeye provides an initial take following the release of Corline’s Q4 2025 report.
Aspo has EBITA improvement potential also this year as Telko and lower group costs contribute, but a...
Redeye views Catella's Q4 2025 results as broadly reassuring.
Redeye comments on SHH’s Q4 2025 report, which landed relatively in-line with the company’s prelimin...
Redeye shares its initial view on Modelon’s Q4 2025 report, which was softer than expected regarding...
Redeye provides its initial take on Moberg Pharma’s Q4 report, where sales greatly exceeded our expe...
Truecaller’s Q4 results align with its preliminary figures, highlighted by a significant margin beat...
* Q4 EBIT of SEK 11m, way below expectations driven by a SEK 151 impairment * Underlying Corporate F...
After a year marked by both progress and setbacks, Xspray enters a pivotal 2026, with two upcoming P...
* EBIT SEK 2m vs FactSet consensus 12m * Sales declined 9% in USD terms, and DPS cut to SEK 2 (8) * ...
Redeye comments on G5’s Q4-resulst which were weaker than expected driven by a soft topline, partly ...
G5's Q4 report looks soft, driven by 5% weaker-than-expected top line which filters through to earni...
Redeye updates on Invisio after Q4-results which was much stronger than expected.
Redeye returns with an update following a softer-than-expected Q4 report.
The most interesting aspect of the Q4 2025 earnings release came on 29 January, when Scanfil publish...
Adjusted EBITA was slightly weaker than we expected in Q4.
